about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditDihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesA randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in childrenAn open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in AsiaEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesArtemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.In vitro selection of Plasmodium falciparum drug-resistant parasite lines.Drug-Resistant Malaria: The Era of ACT.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsNew perspectives on chinese herbal medicine (zhong-yao) research and developmentPharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western KenyaThe efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.The global pipeline of new medicines for the control and elimination of malariaPharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010.Randomized, open-label trial of primaquine against vivax malaria relapse in IndonesiaMonitoring antimalarial safety and tolerability in clinical trials: a case study from UgandaMMV in partnership: the Eurartesim® experience.Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006.Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.Piperaquine pharmacodynamics and parasite viability in a murine malaria model.Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers.Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected childrenExisting antimalarial agents and malaria-treatment strategies.Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre studySafety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy.Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies.A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice.Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice.
P2860
Q21032449-F88B522D-65ED-4403-9D72-5D01EF5277B5Q24201077-C56C2BA7-AD65-408F-A79F-5CBFA124EDC3Q26866187-807AB819-438C-454F-9E6F-C8EF72D1019BQ28474568-AE061A5F-0E47-4E1F-B661-75277678F45AQ28474978-EB40A93D-0C28-4B24-A41F-A93EDF5413F1Q28535686-449E668D-8B2B-4545-813C-6FB290857EF8Q33342827-EC599BA6-6F20-4B5A-9A04-6B68B493C890Q33507089-FC4FD43C-5D66-4011-8149-BA5BF4185168Q33516563-6C1A7A8C-4735-4C1C-990C-2509FE81ED12Q33636206-1BE0F59C-B22F-44DA-AC2B-73B18A1BF594Q34681141-9442783B-1B30-4CBF-B9C0-1DB719C1F2FEQ35055212-0F00EA45-528E-4AED-B866-57014F6081C6Q35102748-75A930FC-4860-4389-ABB5-2157A71F4722Q35139464-6670025F-98C2-4E1C-AD2B-85FA9B7264A4Q35139505-1D106356-0FF7-46B2-9122-E7BE5BA9C79BQ35189138-C2ECF099-8DEA-44AC-983F-B67531C6E6BEQ35834198-9F9DED80-D868-41E2-81EB-2CEAAAD4EDF2Q35960893-3FEB2B8D-3931-41C7-B117-D9B76F3099F8Q36138872-028E33AC-F892-4079-A81C-6475B9CBE4DFQ36320249-62EB7A9D-C52F-4AFE-AD16-12761C929FF5Q36422706-3A4396F6-5825-4922-A3EC-E885D72A8C69Q36436707-8F0FDA7D-9C31-4374-92E7-A41FB9C01840Q36508726-02667FBF-49CF-456B-A7F1-BE1D517927D7Q36558557-53EB81EC-3B21-4FB6-A19E-99111B903A95Q36666980-CF46023F-07EE-4816-A5E0-D8A2DDD5A5A7Q36766577-D648BB2D-2774-4306-BEA6-5A37180672D8Q36952896-30D10DD1-1471-4AFA-93E8-E46D9A1F11F8Q37077284-C650EE3B-8F44-48B5-8BA3-C7779F7DED26Q37086606-FCA969FA-67CE-4E89-BC3C-E5F5F7356BBDQ37223633-C1E9716D-6A3D-4CEB-A0E1-83230B6B907AQ37247580-43CA0364-FE8F-4947-909F-3B3BBFD4590FQ37263344-31E84CBE-83B0-4831-B8ED-671DBF49C9D3Q37460745-E2581B14-C298-473B-B0D3-2681079D3632Q37492591-6A066921-A787-4412-84FE-A2234690B8C8Q37562847-1081B749-56BD-4EB6-8F02-2B0D298C061AQ37607325-CBE64636-E233-4635-BF66-A374B5D5EBFAQ37735182-9210C350-A213-4493-A0AD-8DC097945E02Q38065917-805B3656-600E-427E-8CEC-01A509154774Q38480612-62F05695-9405-4647-912C-F09C99E45790Q38497186-FA0F49D3-9396-4C4E-ACAF-84D3E91BE757
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Efficacy and safety of dihydroartemisinin-piperaquine.
@en
type
label
Efficacy and safety of dihydroartemisinin-piperaquine.
@en
prefLabel
Efficacy and safety of dihydroartemisinin-piperaquine.
@en
P2860
P50
P1476
Efficacy and safety of dihydroartemisinin-piperaquine.
@en
P2093
P2860
P304
P356
10.1016/J.TRSTMH.2007.05.018
P577
2007-07-19T00:00:00Z